Aldeyra The
ALDXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 8, 2025 | Jefferies | Clara Dong | $7.00(+25%) | $5.62 | TheFly |
| Oct 3, 2024 | Oppenheimer | Justin Kim | $12.00(+133%) | $5.14 | StreetInsider |
| Apr 3, 2024 | Oppenheimer | Justin Kim | $10.00(+182%) | $3.55 | StreetInsider |
| Apr 2, 2024 | H.C. Wainwright | Matt Caufield | $10.00(+206%) | $3.27 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Neutral | Sep 30, 2026 |
| BTIG | maintain | Buy | Sep 29, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Mar 18, 2026 |
| BTIG | maintain | Buy | Nov 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 19, 2025 |
| BTIG | maintain | Buy | Apr 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2024 |
| Oppenheimer | maintain | Outperform | May 6, 2024 |
| Oppenheimer | upgrade | Perform →Outperform | Apr 3, 2024 |
| Citigroup | maintain | Buy | Oct 17, 2023 |
| Oppenheimer | downgrade | Outperform →Perform | Oct 17, 2023 |
| Oppenheimer | maintain | Outperform | Aug 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 30, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 22, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 16, 2023 |
| Citigroup | maintain | Buy | Jun 1, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 10, 2023 |
| Citigroup | maintain | Buy | Mar 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 1, 2023 |
| Citigroup | maintain | Buy | Nov 21, 2022 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.06 | $-0.11 | — | $2.5M |
| Aug 6, 2026 | $-0.09 | $-0.09 | — | $31.3M |
| May 7, 2026 | $-0.06 | $-0.13 | — | — |
| Feb 27, 2026 | $-0.11 | $-0.14 | — | $4.8M |
| Nov 5, 2025 | $-0.13 | $-0.17 | — | $24.3M |
| Aug 7, 2025 | $-0.16 | $-0.21 | — | — |
| May 14, 2025 | $-0.17 | $-0.25 | — | -$666.7K |
| Feb 28, 2025 | $-0.27 | $-0.25 | $244.5K | — |
News
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to the company's intent to submit a formal dispute resolution request tied to its reproxalap program.
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease.
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The FDRR, which is expected to be reviewed by the FDA's Office of New Drug.
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease. A live audio webcast and slide presentation will be accessible from.